July 9, 2021 -- I-Mab announced it has signed onto two new collaborations with biotech companies in China in what company leaders say will strengthen its innovation pipeline.
The company is collaborating with Immorna and NeoX Biotech, who will receive undisclosed upfront and/or milestone payments.
I-Mab will develop novel anticancer antibody therapeutics through Immorna's self-replicating mRNA platform. I-Mab will meanwhile work with NeoX Biotech for up to 10 novel biologics programs using NeoX's artificial intelligence algorithm.
The announcement is a new addition to I-Mab's existing collaboration agreements with Complix for its cell-penetrating antibody platform and Affinity for its masking antibody platform in March 2021.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
